1. Scrip
  2. >>Business
  3. >>Financing

Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties

 
• By Jessica Merrill

Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.

A man and a women hands hold a money bags in the public park for loans to planned investment in the future concept.
Blackrock Made A Multi-Pronged Investment In Alnylam • Source: Shutterstock

Alnylam Pharmaceuticals Inc. closed an impressive $2bn financing from the investment firm Blackstone, despite the volatile environment caused by COVID-19. The biopharma said it will use the investment to fund the development of more RNAi drugs and achieve long-term sustainability, announcing the multi-pronged agreement on 13 April.

"This new relationship with Blackstone provides Alnylam with very significant capital that we believe secures our bridge towards achieving a self-sustainable financial profile without the need to access the equity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.